DiObex to Present at Canaccord Adams Diabetes and Obesity Conference

SAN FRANCISCO, June 4 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic disease, announced today that CEO David Cory will deliver a corporate presentation at the upcoming Canaccord Adams Diabetes and Obesity Conference in San Francisco, California. The DiObex presentation will take place on Friday, June 6th at 9 a.m. at the Nikko Hotel, Monterey II Room.

About DiObex

DiObex is a biotechnology company engaged in the development of novel products for metabolic disease. DIO-901 (very low dose glucagon) is in development in two convenient delivery forms for the prevention of nocturnal hypoglycemia induced by insulin intensification. Insulin-induced hypoglycemia, which occurs most frequently at night, is a major limitation in the aggressive management of hyperglycemia in diabetes patients. The DIO-901 disposable device will be applied before bedtime to provide continuous subcutaneous delivery of glucagon during the night. The DIO-901 extended release formulation will be delivered via auto injector before bedtime to slowly release glucagon during the night. DIO-901 has received Fast Track status from the FDA. For more information, visit http://www.diobex.com.

SOURCE DiObex, Inc.